Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to $283000.0.

  • Aytu Biopharma's Share-based Compensation rose 8741.72% to $283000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $649000.0, marking a year-over-year decrease of 5635.51%. This contributed to the annual value of $576000.0 for FY2025, which is 8022.66% down from last year.
  • As of Q4 2025, Aytu Biopharma's Share-based Compensation stood at $283000.0, which was up 8741.72% from $114000.0 recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Share-based Compensation registered a high of $3.1 million during Q4 2022, and its lowest value of $113000.0 during Q2 2025.
  • Its 5-year average for Share-based Compensation is $889550.0, with a median of $901000.0 in 2023.
  • Per our database at Business Quant, Aytu Biopharma's Share-based Compensation skyrocketed by 47651.52% in 2021 and then plummeted by 8286.07% in 2025.
  • Aytu Biopharma's Share-based Compensation (Quarter) stood at $1.2 million in 2021, then surged by 149.55% to $3.1 million in 2022, then crashed by 73.26% to $820000.0 in 2023, then tumbled by 81.59% to $151000.0 in 2024, then surged by 87.42% to $283000.0 in 2025.
  • Its last three reported values are $283000.0 in Q4 2025, $114000.0 for Q3 2025, and $113000.0 during Q2 2025.